Lithium: a key to the genetics of bipolar disorder
AUTOR(ES)
Cruceanu, Cristiana
FONTE
BioMed Central
RESUMO
Since the 1950s, lithium salts have been the main line of treatment for bipolar disorder (BD), both as a prophylactic and as an episodic treatment agent. Like many psychiatric conditions, BD is genetically and phenotypically heterogeneous, but evidence suggests that individuals who respond well to lithium treatment have more homogeneous clinical and molecular profiles. Response to lithium seems to cluster in families and can be used as a predictor for recurrence of BD symptoms. While molecular studies have provided important information about possible genes involved in BD predisposition or in lithium response, neither the mechanism of action of this drug nor the genetic profile of bipolar disorder is, as yet, completely understood.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2768965Documentos Relacionados
- Risk factors of thyroid abnormalities in bipolar patients receiving lithium: a case control study
- Risk of suicide in bipolar disorder is least with lithium
- Lithium and motor vehicle crashes: Perhaps bipolar disorder is the risk, not its treatment
- Lithium side-effects and predictors of hypothyroidism in patients with bipolar disorder: sex differences
- How should lithium-induced thyroid dysfunction be managed in patients with bipolar disorder?